| 1 |
33593942 | AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. | 2021 Apr |
1 |
| 2 |
29861877 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. | 2018 May 18 |
1 |
| 3 |
26142736 | Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer. | 2015 Dec |
5 |
| 4 |
24156021 | Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer. | 2013 Aug |
6 |
| 5 |
22740861 | Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study. | 2012 Jan |
2 |
| 6 |
20628391 | UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. | 2010 Aug 10 |
2 |
| 7 |
20811661 | Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. | 2010 Oct |
2 |
| 8 |
19436196 | Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. | 2009 Jul |
2 |
| 9 |
19528468 | Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. | 2009 Jun |
3 |
| 10 |
18357380 | Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. | 2008 Apr |
8 |
| 11 |
19262706 | Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. | 2007 Sep |
7 |
| 12 |
16251201 | Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. | 2006 Jan |
1 |
| 13 |
16897968 | [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. | 2006 Jun |
2 |
| 14 |
15709193 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. | 2005 Feb 1 |
2 |
| 15 |
15996331 | [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]. | 2005 May |
1 |
| 16 |
16077970 | Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. | 2005 Sep |
3 |
| 17 |
14962716 | Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. | 2004 Mar |
3 |
| 18 |
15354215 | Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. | 2004 Oct 4 |
2 |
| 19 |
15634630 | A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. | 2004 Dec |
2 |
| 20 |
12482336 | Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. | 2002 Nov |
1 |
| 21 |
11705873 | Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. | 2001 Nov |
1 |
| 22 |
10803925 | Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. | 2000 |
2 |
| 23 |
9515577 | Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. | 1998 Mar 1 |
1 |
| 24 |
8664184 | Summary of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. | 1995 Sep |
1 |